At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 837 enrolled
Drug / intervention
XOMA 985 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
In Brief
A Phase 3 clinical trial evaluating XOMA 985, Amlodipine Besylate, and 1 other intervention for Essential Hypertension. Completed, enrolled 837 participants across 48 sites.
Detailed Summary
The purpose of the study is to evaluate the safety and efficacy of a fixed-dose combination drug compared to two other drugs (monotherapies) in controlling hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2012
First PostedMar 2012
Primary CompletionFeb 2013
TodayJul 2026
First PostedMar 19, 2012
Enrollment StartFeb 1, 2012
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 14.3 years ago
Interventions
XOMA 985drug
PERa/AMLb capsule taken once daily by mouth for six weeks
Amlodipine Besylatedrug
AMLb capsule taken once daily by mouth for six weeks
Perindopril Erbuminedrug
PERe capsule taken once daily by mouth for six weeks